SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001562762-21-000494
Filing Date
2021-12-23
Accepted
2021-12-23 16:38:23
Documents
80
Period of Report
2021-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q vaxxq310q.htm   iXBRL 10-Q 2067333
7 EX-31.1 ex311.htm EX-31.1 10236
8 EX-31.2 ex312.htm EX-31.2 10346
9 EX-32.1 ex321.htm EX-32.1 5910
10 EX-32.2 ex322.htm EX-32.2 6066
  Complete submission text file 0001562762-21-000494.txt   7539678

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA vaxx-20210930.xsd EX-101.SCH 65894
3 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE vaxx-20210930_cal.xml EX-101.CAL 78548
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE vaxx-20210930_def.xml EX-101.DEF 415822
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE vaxx-20210930_lab.xml EX-101.LAB 489709
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE vaxx-20210930_pre.xml EX-101.PRE 543230
74 EXTRACTED XBRL INSTANCE DOCUMENT vaxxq310q_htm.xml XML 851729
Mailing Address 1717 MAIN STREET SUITE 3388 DALLAS TX 75201
Business Address 1717 MAIN STREET SUITE 3388 DALLAS TX 75201 (254) 244-5739
Vaxxinity, Inc. (Filer) CIK: 0001851657 (see all company filings)

IRS No.: 862083865 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-41058 | Film No.: 211517609
SIC: 2834 Pharmaceutical Preparations